B · Normal
[InnoCare: Zolecitinib will be included in the 2026 National Reimbursement Directory] On November 15, InnoCare (688428.SH) announced that the company’s independently developed new generation TRK inhibitor zolecitinib tablets have been included in the new version of the National Reimbursement Directory for the treatment of adults and adolescent patients with solid tumors over the age of 12 who carry NTRK fusion genes. The drug's medical insurance payment management classification is Category B, and the agreement is valid from January 1, 2027 to December 31, 2028.
Comments